Journal of Parkinsons Disease

Papers
(The H4-Index of Journal of Parkinsons Disease is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
This is NOT the End for Immunotherapy in Parkinson’s Disease – A Perspective from Early Drug Development Scientists115
Clinical Trial Highlights: Modulators of Mitochondrial Function92
Introduction: The Earliest Phase of Parkinson’s Disease: Possibilities for Detection and Intervention74
Chronotropic Incompetence in Parkinson’s Disease: A Possible Marker of Severe Disease Phenotype?61
One-year practice effects predict long-term cognitive outcomes in Parkinson's disease60
Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression58
A framework to standardize gait study protocols in Parkinson's disease56
A Multisensory Deficit in the Perception of Pleasantness in Parkinson’s Disease52
Are Preformed Fibrils a Model of Parkinson’s Disease?50
May Bradykinesia Features Aid in Distinguishing Parkinson’s Disease, Essential Tremor, And Healthy Elderly Individuals?48
Cost-Effectiveness and Cost-Utility of Early Levodopa in Parkinson’s Disease47
Imaging Biomarkers in Prodromal and Earliest Phases of Parkinson’s Disease46
Ethical Considerations for Identifying Individuals in the Prodromal/Early Phase of Parkinson’s Disease: A Narrative Review46
Jellinger K, “Parkinson’s Disease and Dementia with Lewy Bodies: One and the Same”45
Post-Traumatic Stress Disorder and Risk of Parkinson’s Disease in a Veteran Cohort44
Reply to the Letter to the Editor: Stefani A, “Is it too early to Underrate Genetic onto PD Pathogenesis? Reflections on History”43
Effects of Very Low- and High-Frequency Subthalamic Stimulation on Motor Cortical Oscillations During Rhythmic Lower-Limb Movements in Parkinson’s Disease Patients43
Evading the Immune System: Immune Modulation and Immune Matching in Cell Replacement Therapies for Parkinson’s Disease42
Atrophy-related corticospinal changes in advanced Parkinson's disease are associated with the genetic etiology of the disease42
Rapid Voluntary Blinking as a Clinical Marker of Parkinson’s Disease41
No Higher Risk-Seeking Tendencies or Altered Self-Estimation in a Social Decision-Making Task in Patients with Parkinson’s Disease40
Apathy Reflects Extra-Striatal Dopaminergic Degeneration in de novo Parkinson’s Disease40
Glucocerebrosidase Activity is Reduced in Cryopreserved Parkinson’s Disease Patient Monocytes and Inversely Correlates with Motor Severity40
Cerebral Small Vessel Disease Is Associated with Motor, Cognitive, and Emotional Dysfunction in Multiple System Atrophy38
The fixel GI Parkinson's research and integrated support model (PRISM)38
Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson’s Disease37
A possible pathway to freezing of gait in Parkinson's disease37
Current Update on Clinically Relevant Sleep Issues in Parkinson’s Disease: A Narrative Review37
Real-World Evaluation of the Feasibility, Acceptability and Safety of a Remote, Self-Management Parkinson’s Disease Care Pathway: A Healthcare Improvement Initiative37
Early-Onset Parkinson’s Disease: Creating the Right Environment for a Genetic Disorder36
Is There an Association Between Parkinson’s Disease and Periodontitis? A Systematic Review and Meta-Analysis35
Predictive Value of Verbatim Parkinson’s Disease Patient-Reported Symptoms of Postural Instability and Falling35
Clinical Trial Highlights – Aerobic Exercise for Parkinson’s Disease35
A Coalition to Advance Treatments for Parkinson’s Disease, Dementia with Lewy Bodies, and Related Disorders34
The Role of Microelectrode Recording and Stereotactic Computed Tomography in Verifying Lead Placement During Awake MRI-Guided Subthalamic Nucleus Deep Brain Stimulation for Parkinson’s Disease34
Metabotropic Glutamate Receptor 4 (mGlu4) Positive Allosteric Modulators Lack Efficacy in Rat and Marmoset Models of L-DOPA-Induced Dyskinesia34
0.064230918884277